drugset / Trial / NCT01138163
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-10
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bavituximab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Bavituximab | Monoclonal antibody | 3 mg/kg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |